MiniMed (MMED) reported a fiscal Q4 loss Wednesday of $0.68 per diluted share, unchanged from a year earlier.
Revenue for the quarter ended April 24 was $837 million, up from $724 million a year earlier.
Analysts polled by FactSet expected $827.9 million.
For fiscal 2027, the company expects organic revenue growth of approximately 10%.
MiniMed shares were up 5.7% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.